ONO Pharmaceutical Enters Agreement with Seikagaku for Co-Development and Marketing of Gel-One in Japan, Currently in Phase III Trials

ONO Pharmaceutical Co. Ltd. has announced a definitive agreement with Seikagaku Corporation for the co-development and marketing collaboration on Gel-One, a treatment for osteoarthritis in Japan. The agreement grants Ono co-development and exclusive marketing rights for Gel-One in Japan, where the product is currently undergoing Phase III clinical studies and a long-term safety study. These studies include trials for osteoarthritis of the knee and hip, alongside a comprehensive safety evaluation for both joints. The companies aim to expedite the clinical studies to secure manufacturing and marketing authorization at the earliest possible date. The results of these studies have not yet been presented. Under the terms of the agreement, Ono will pay Seikagaku tiered royalties based on the future progress of development and marketing. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ONO Pharmaceutical Co. Ltd. published the original content used to generate this news brief on August 07, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT) Original Document: here